Nicholas Simon


Nicholas “Nick” J. Simon became a Gladstone trustee in 2017. He is co-founder and managing director of Clarus, a leading global investment firm dedicated to life sciences. Mr. Simon has over 30 years of operating and investment experience in the biopharmaceutical industry, including leadership positions held at Genentech and the healthcare venture capital firm MPM Capital.

Mr. Simon is currently a member of the Board of Directors of Gritstone Oncology, Lycera Corporation, Nuvelution Pharma and Sientra. He has also served as a board member for numerous other private and public life science companies, including Achillion, Avanir Pharmaceuticals, Barrier Therapeutics, Biovitrum AB, CoTherix, InterMune, Pearl Therapeutics, Quatrx Pharmaceuticals, Rigel, and Sangstat.

Mr. Simon received a BS degree in microbiology from the University of Maryland and an MBA from Loyola University.